Skip to main content
. Author manuscript; available in PMC: 2009 Aug 15.
Published in final edited form as: Cancer Res. 2008 Aug 15;68(16):6643–6651. doi: 10.1158/0008-5472.CAN-08-0850

Figure 6. GSK3 inhibition potentiates the anti-tumor action of other cytotoxic drugs in vitro and in vivo.

Figure 6

(A) TRAIL acts synergistically with enzastaurin in glioma cell killing. (B) Overexpression of c-MYC kills glioma cells. TRAIL enhances cell death caused by c-MYC overexpression. (C) Combination of enzastaurin with carboplatin results in significantly reduced tumor volume in a mouse subcutaneous U87 xenograft model. (D) Combination of enzastaurin with carboplatin prolongs survival in U87 intracranial xenograft model.

HHS Vulnerability Disclosure